knee osteoarthritis
Conditions
Interventions
Experimental Group:Gua sha
Control Group: Diclofenac Diethylamine Emulgel
Sponsors
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with Cold-Dampness Obstruction Type KOA: (1) Meet the diagnostic criteria for KOA in Western medicine (refer to the Diagnosis and Treatment Guidelines for Osteoarthritis (2018 Edition) formulated by the Orthopaedic Branch of the Chinese Medical Association) and the TCM syndrome differentiation criteria (Guidelines for TCM Diagnosis and Treatment of Knee Osteoarthritis (2020 Edition)); (2) Aged 40-80 years regardless of gender; (3) KL grade I-II; (4) Patients who have not received other non-surgical treatments for KOA or who have received other non-surgical therapies and are willing to undergo a 7-day washout period; (5) Willing to participate in the study with good compliance and voluntary signing of the informed consent form. Healthy Volunteers: (1) Healthy volunteers undergoing physical examinations at our hospital; (2) Aged 40-80 years regardless of gender; (3) No history of knee pain or discomfort; (4) Willing to participate in the study with good compliance and voluntary signing of the informed consent form.
Exclusion criteria
Exclusion criteria: Patients with Cold-Dampness Obstruction Type KOA: (1) KOA accompanied by acute synovitis or acute infection; (2) Patients with knee joint tuberculosis tumors rheumatic arthritis or rheumatoid arthritis; (3) Patients with complications affecting the knee joint such as psoriasis syphilitic neuropathy ochronosis metabolic bone disease acute trauma etc.; (4) Patients who have received systemic or intra-articular hormone therapy within the past 2 months or who have undergone intra-articular injections or arthroscopy of the knee joint within the past 3 months; (5) Patients with a history of knee surgery severe trauma or skin lesions in the scraping area within the past 3 months or other conditions affecting local scraping; (6) Patients who are currently participating in or planning to participate in other clinical trials; (7) Patients who require painkillers for chronic or recurrent pain other than KOA such as acetaminophen non-steroidal anti-inflammatory drugs opioid analgesics compound over-the-counter drugs with analgesic effects or traditional Chinese medicine or topical analgesics; (8) Patients who are pregnant menstruating or have severe liver or kidney diseases cardiovascular diseases metabolic diseases skin diseases mental illnesses bleeding tendencies or coagulation disorders; (9) Patients with cognitive or language dysfunction; (10) Patients with allergic constitutions or immune system diseases; (11) Cases deemed unsuitable for the study by researchers such as those with frequently changing work environments that may lead to loss to follow-up. Healthy Volunteers: (1) Pregnant or lactating women; (2) Individuals with severe primary cardiopulmonary insufficiency liver or kidney diseases or hematopoietic system diseases; (3) Individuals with cognitive or language dysfunction; (4) Individuals with primary or secondary infectious diseases such as pneumonia urinary tract infections cholecystitis etc.; (5) Individuals with a history of metabolic diseases such as metabolic syndrome; (6) Individuals with mental or intellectual disabilities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WOMAC; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Score;Lequesne;VAS; | — |
Countries
China
Contacts
Public ContactYan Zhu
Nanjing University of Chinese Medicine (NJUCM)
Outcome results
None listed